Sun Pharma Strikes US Drug Price Deal

Sun Pharmaceutical Industries has entered into a "Most Favoured Nation" agreement with the US government. Under this pact, the company will offer its prescription and future innovative drugs in the US at prices aligned with the lowest rates paid by other developed nations. This initiative, part of a Trump administration program, seeks to enhance healthcare affordability for low-income Americans.

Analysts and industry experts suggest that the financial impact on Sun Pharma will likely be minimal, potentially affecting only a small portion of its specialty portfolio. The US market contributes approximately 27% to Sun Pharma's global revenue, and this agreement is viewed as a recognition of the company's investment in the American market. Further details of the agreement remain confidential.